Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary
<p>Abstract</p> <p>Background</p> <p>The cervical cancer screening program implemented in Hungary to date has not been successful. Along with screening, vaccination is an effective intervention to prevent cervical cancer. The aim of this study was to assess the cost-eff...
Saved in:
Main Authors: | Vokó Zoltán (Author), Nagyjánosi László (Author), Kaló Zoltán (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2012-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule
by: Maria Julieta Germar, et al.
Published: (2017) -
Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
by: Kohli Michele, et al.
Published: (2012) -
Monitoring the safety of the adjuvanted human papillomavirus vaccine, HPV-16/18-AS04: Protocol for a cohort study using electronic health records in Yinzhou, China
by: Junting Yang, et al.
Published: (2024) -
Incremental cost of premature birth - a public health care payer perspective from Hungary
by: Gábor Kovács, et al.
Published: (2023) -
A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil®)
by: Vandana A Govan
Published: (2008)